Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction

Neoleukin Therapeutics, Inc. announced the completion of the previously disclosed merger transaction with Aquinox Pharmaceuticals, Inc. Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol “NLTX” beginning on Monday, August 12, 2019, on the Nasdaq Global Market.

Following the close of the transaction, and after giving effect to conversion of preferred shares into common subject to a stockholder vote, there are expected to be 38.3 million total shares of common stock outstanding. The corporate headquarters are now located in Seattle, Washington at Neoleukin’s existing facility. As of June 30, 2019, after giving effect to the merger, including merger-related expenses, the company has approximately $65 million in cash and cash equivalents, which it believes will be sufficient to fund operations through 2021.